THU0440 Ixekizumab Provides Sustained Improvement up To 52 Weeks of Disease Activity as Assessed by Composite Measure Scores in Biologic Disease-Modifying Antirheumatic Drug (bDMARD)-Naive Patients with Active Psoriatic Arthritis
Coates, L.C.; Husni, M.E.; Shuler, C.L.; Carlier, H.; Lin, C.-Y.; Mou, J.; Lee, C.H.; Mease, P.J.
- 期刊名称Annals of the Rheumatic Diseases
- 作者Coates, L.C.; Husni, M.E.; Shuler, C.L.; Carlier, H.; Lin, C.-Y.; Mou, J.; Lee, C.H.; Mease, P.J.
- 卷第75卷
- 印刷ISSN0003-4967
- 电子ISSN1468-2060
- 文件大小288.67KB
- 发表时间2016-06
- DOI10.1136/annrheumdis-2016-eular.1397
- 页码349-350